Early diagnosis of idiopathic pulmonary fibrosis (IPF) is definitely a challenge. Several studies have been investigating how to achieve this goal. IPF is the most common type of idiopathic interstitial pneumonia, the median age at diagnosis is approximately 65 years and it's more common in smokers and males [1]. To date, there are only two therapeutic options available (pirfenidone and nintedanib) that have shown to be effectively slowing disease progression in terms of forced vital capacity (FVC) [2] with a further decrease in the risk of acute exacerbations for nintedanib [3].
